Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397820 | PMC |
| http://dx.doi.org/10.1016/j.abd.2025.501192 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Paradoxical lichenoid reaction during dupilumab treatment- a case report and literature review.
An Bras Dermatol
August 2025
Department of Dermatology, First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China; Fujian Dermatology and Venereology Research Institute, First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China; Key Laboratory of Skin Cancer, Fujian Higher Education Instituti
Concurrent Eruptive Melanocytic Nevi and Multiple Keratoacanthomas Induced by Encorafenib.
Cureus
September 2024
Oncology, Biokliniki Athinon, Athens, GRC.
Article Synopsis
- - A case study discusses a 64-year-old male with metastatic colorectal cancer who developed severe itching and new skin lesions after treatment with encorafenib and panitumumab, medications targeting cancer pathways.
- - The patient showed a mix of skin lesions, including benign moles and keratoacanthomas, with further evaluation confirming a link between the skin reactions and the use of encorafenib, as validated by the Naranjo scale.
- - Stopping the medications led to significant improvement in skin lesions, highlighting the importance of ongoing skin assessments for patients on BRAF inhibitors to manage side effects effectively.
Critical Review-A Tribute to Louis Brocq Lymphomatoid Papulosis, the Key in Exploring the Relationship of Parapsoriasis and Mycosis Fungoides.
Am J Dermatopathol
November 2023
Kossard Dermatopathologists, Laverty Pathology, Macquarie Park, NSW, Australia.
Both parapsoriasis and LyP appear clinically as inflammatory dermatoses with a paradoxical link to cMF. A key element in addressing the relationship of parapsoriasis and MF were the results of the French and Dutch long-term registries tracking the emergence of lymphomas in the setting of LyP. Both cMF and cALCL emerged almost equally in these long-term studies.
View Article and Find Full Text PDFThe dark side of the moon: the immune-mediated adverse events of IL-17A/IL-17R inhibition.
J Dermatolog Treat
August 2022
Dermatology Unit, Department of Medicine, University of Padua, Padua, Italy.
As aberrant IL-17 signaling plays a critical role in the pathogenesis of psoriasis, biologic agents targeting this pathway have become an important weapon against this disease. Some biologic agents such as IL-17 inhibitors (secukinumab and ixekizumab) and the IL-17 receptor (IL17R) inhibitor (brodalumab) are relatively safe, tolerable and efficacious drugs. Nevertheless, side effects of IL-17 pathway inhibition occur.
View Article and Find Full Text PDFLichen planopilaris induced by infliximab: A case report.
SAGE Open Med Case Rep
January 2020
Division of Dermatology, Department of Medicine, Queen's University and Hotel Dieu Hospital, Kingston, ON, Canada.
Infliximab is a tumor necrosis factor-alpha inhibitor used to treat a range of inflammatory diseases. Most reports of cutaneous eruptions from tumor necrosis factor-alpha inhibitors have described the paradoxical development of psoriasis or psoriasiform drug reaction. In our report, we present a 31-year-old female with inflammatory bowel disease who developed an unusual lichenoid drug reaction to infliximab involving the hair follicles, resulting in progressive global alopecia.
View Article and Find Full Text PDF